Cholangiocarcinoma Clinical Trials 2024

What are the top hospitals conducting cholangiocarcinoma research?

When it comes to advancing treatment options for cholangiocarcinoma, several leading hospitals are at the forefront of groundbreaking clinical trials. In New york City, Memorial Sloan Kettering Cancer Center leads the way with an impressive 13 active trials dedicated to cholangiocarcinoma and a total of 25 completed studies on this rare cancer that affects the bile ducts. Since their first recorded trial in 2000, Memorial Sloan Kettering has been committed to finding new ways to combat this challenging disease. Boston's Massachusetts General Hospital is also making significant contributions in the field with nine ongoing cholangiocarcinoma trials and a history of 19 completed studies since their first trial in 2006.

Heading south to Houston, Texas, The University of Texas MD Anderson Cancer Center is actively conducting eight clinical trials for cholangiocarcinoma and has already accomplished eleven previous investigations since initiating its first trial in 2014. Additionally, there are two other renowned MD Anderson Cancer Centers within Houston which have made notable progress in addressing this condition: one boasts eight ongoing clinical trials with a total of fifteen past investigations dating back to their initial trial in 2011 while another center currently runs six active clinical tests while holding responsibility of previously held sixteen experiments ever conducted; theirs can be traced back only seven years ago since starting their pioneering investigation on such cases.

These esteemed institutions serve as beacons of hope for individuals diagnosed with cholangiocarcinoma and showcase the tireless efforts being made by medical professionals across different locations. Through these collective endeavors, researchers aim not only to improve outcomes for patients but also shed light on new strategies for managing this complex cancer type. Each small step taken through these clinical trials brings us closer to unlocking better treatments and ultimately enhancing the quality of life for those affected by cholangiocarcinoma around the world.

Which are the best cities for cholangiocarcinoma clinical trials?

When it comes to cholangiocarcinoma clinical trials, several cities are at the forefront of research and innovation. Houston, Texas leads with 37 active trials focused on investigating treatments like NGM831, RLY-4008, and NGM438. New york, New York follows closely behind with 32 ongoing studies exploring gavo-cel, LYT-200, and Gemcitabine. Boston, Massachusetts also has 32 active trials examining Cobimetinib, pembrolizumab, and LY3410738. Los Angeles, California and Anchorage Alaska each have 26 active trials exploring various treatment options including Nivolumab and chemotherapy combinations. These cities provide individuals diagnosed with cholangiocarcinoma access to a wide range of cutting-edge clinical trials that hold promise for improved outcomes in the fight against this challenging disease.

Which are the top treatments for cholangiocarcinoma being explored in clinical trials?

Exciting advancements are underway in clinical trials exploring treatments for cholangiocarcinoma. Gemcitabine, a well-established drug since 2002, is currently the frontrunner with five active trials and an impressive track record of 51 all-time cholangiocarcinoma studies. Not far behind is durvalumab, introduced in 2016, which shows promise with two ongoing trials and a total of 16 past cholangiocarcinoma trials. Tivozanib enters the scene more recently in 2021 but has already garnered interest with two active trials dedicated to treating this form of cancer. Lastly, olaparib completes the list by participating in two current studies after its introduction into research for cholangiocarcinoma back in 2019. These developments offer renewed hope to patients battling this challenging disease.

What are the most recent clinical trials for cholangiocarcinoma?

The field of cholangiocarcinoma research is rapidly advancing, with several recent clinical trials offering new hope for patients. Among these trials is the investigation of tinengotinib, an 8 mg QD treatment in Phase 3 that aims to combat this aggressive form of cancer. Additionally, a Phase 2 trial known as Arm A explores potential interventions specifically tailored for cholangiocarcinoma patients. Another promising study combines gemcitabine, cisplatin, durvalumab, and yttrium-90 selective internal radiation therapy to target this challenging disease. Furthermore, significant strides have been made in understanding the role of LSTA1 arm and Cohort 2 (HCC) treatments in advanced head and neck squamous cell carcinoma associated with cholangiocarcinoma. These groundbreaking studies provide renewed optimism for individuals affected by cholangiocarcinoma.

What cholangiocarcinoma clinical trials were recently completed?

Several recent clinical trials have advanced the fight against cholangiocarcinoma, a challenging cancer of the bile ducts. In August 2020, Celldex Therapeutics concluded a trial investigating CDX-527, and in November 2019, the National Cancer Institute completed its study on MVT-5873. Mayo Clinic's trial examining Trifluridine and Tipiracil Hydrochloride wrapped up in October 2019, while another NCI-sponsored trial exploring Mesothelin Expression ended in August of that same year. These trials represent significant efforts to find more effective treatments for cholangiocarcinoma patients and underscore the commitment of researchers in this field.